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Reprograming lipid metabolism, one of the major metabolic alterations in cancer, is
believed to play an essential role in cancer development, but the exact molecular
mechanism remains elusive. Here, we present a computational study of transcriptomic
data of HCC with HCV etiology to investigate how lipid metabolism alters during HCC
progression. Our analyses reveal that: (1) cancer tissue cells tend to synthesize fatty
acids de novo and its phospholipid derivatives; (2) lipid catabolism and fatty acid
oxidation are remarkably down-regulated in HCC; (3) the lipid metabolism in HCC
is largely independent of lipids in blood circulation; (4) stage-specific co-expression
networks for lipid metabolic genes were identified during HCC progression; and (5) the
expression levels of several lipid metabolic genes that are differentially expressed or co-
expressed specifically at the HCC stage have a strong correlation with cancer survival.
Overall, the results provide detailed information about the reprogramed lipid metabolism
in HCV-derived HCC.
Keywords: hepatocellular cancer, lipid metabolism, de novo synthesis of fatty acid, gene set enrichment, gene
co-expression
INTRODUCTION
Liver cancer is the third leading cause of cancer-related death worldwide, and has had
approximately 840,000 new cases per year in the recent history (Bray et al., 2018). Hepatocellular
cancer (HCC) accounts for 90% of the primary liver cancer cases, and cholangiocarcinoma, derived
from the epithelial lining of the bile duct, is a distant second and rare (Llovet et al., 2016). A few
risk factors have been identified for HCC, such as viral infection, alcohol over dose, smoking,
ingestion of aflatoxin B1, and non-alcoholic steatohepatitis. Infection with hepatitis B virus (HBV)
and hepatitis C virus (HCV) is a major risk factor for HCC worldwide. For example, up to 80% of
HCC is attributable to HBV or HCV (Perz et al., 2006).
Hepatocellular cancer development generally consists of a few stages, namely chronic
inflammation, advanced hepatic fibrosis or cirrhosis, dysplastic nodules, and HCC (Llovet
et al., 2016). Of all HCC cases, 80–90% have cirrhosis prior to cancer development
(Caldwell and Park, 2009), largely due to chronic inflammation for an extended period of time.
It was estimated that 20–30% of people with HBV and HCV infection will develop cirrhosis 20–
30 years after the infection. Only a small portion of HCC with HBV or HCV etiology developed
without cirrhosis.
Abbreviations: DEG, differentially expressed gene; HCC, hepatocellular cancer; LMG, lipid metabolic gene.
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The molecular mechanism of the formation and progression
of HCC remains elusive, although great progress has been made.
Considerable genomic alterations induced by hepatitis virus
infection have been believed to contribute to the hepatocyte
malignant transformation through various oncogenic signaling
pathways, such as Wnt/β-catenin, PI3K/AKT/mTOR, TGF-β,
insulin-like growth factor receptor (IGFR), and MAPK signaling
pathways (Bruix et al., 2015; Li and Wang, 2016; Llovet et al.,
2016). Driver mutations in HCC have also been shown to
affect the inactivation of p53, chromatin remodeling, alternative
splicing, and the induction of the oxidative stress response
pathways, which may play a role in carcinogenesis and cancer
progression (Ralph et al., 2010; Bruix et al., 2015; Pon and Marra,
2015; Climente-González et al., 2017).
Metabolic reprograming has a tight and complex relationship
with genetic mutations in cancerous cells. Although multiple
mutations along with the dysregulation of various signaling
pathways have long been considered as a major molecular
cause of tumorigenesis, metabolic alterations triggered by
the oncogenic mutations and signaling, which are probably
preferentially selected by the pre-cancerous or cancerous cells
to survive in the stressful cellular microenvironment, are now
shown to play much more critical roles than previously thought
in cancer development (Cairns et al., 2011). It is even possible
that some metabolic alterations occur before oncogenic signals
and drive malignant transformation.
Metabolic reprograming in cancer includes alterations in
the metabolisms of carbohydrates, lipids, and amino-acids
(Zhang and Du, 2012; Yang et al., 2013; Hirschey et al., 2015).
The dysregulation of lipid metabolism is one of the major
reprogramed metabolisms in cancer. The most studied lipid
metabolic reprograming in cancer is the elevated de novo
synthesis of fatty acids and downstream lipogenesis (Zhang
and Du, 2012). Like proliferative embryonic cells, cancer cells
prefer to synthesize de novo fatty acids for use rather than
importing them from circulation as normal somatic cells do.
It has been reported that the increased level of fatty acids in
cancer cells will be esterified to lipids (e.g., phospholipids),
which can be used as building blocks in the cell membrane
or for energy production via β-oxidation (Swinnen et al.,
2006; Menendez and Lupu, 2007; Zhang and Du, 2012). In
addition, such lipids can also serve as signaling molecules
such as ceramide (a sphingolipid). It is noteworthy that
cancer cells tend to simultaneously up-regulate their lipid
synthesis and degradation processes (Nomura et al., 2010;
Zhang and Du, 2012).
The altered lipid metabolism is now believed to contribute
to cancer initiation and progression (Santos and Schulze, 2012;
Baenke et al., 2013; Beloribi-Djefaflia et al., 2016; Corbet and
Feron, 2017; Cheng et al., 2018), but the exact molecular
mechanisms are not fully understood yet due to the high
complexity and temporal spatial heterogeneity of tumors. In
addition, the reprogramed lipid metabolism seems to not
function alone, instead it is coupled with other reprogramed
metabolisms. For example, increased lipid synthesis generally
requires changes in glucose and/or amino acid metabolisms,
which may serve as the substrates for fatty acid synthesis via citric
TABLE 1 | A summary of the differentially expressed genes.
Cirrhotic Dysplastic HCC
Up-regulated 184 (19:3) 43 (3:0) 360 (87:8)
Down-regulated 51(6:0) 31 (4:0) 467 (93:46)
Total 235(25:3) 74 (7:0) 827 (180:54)
Values inside the parentheses are the numbers of differentially expressed LMGs
and stage-specific LMGs, respectively.
acid, or increased utilization of β-oxidation may divert glucose
and amino acids toward a purpose other than ATP production.
Here, we present a computational analysis of gene expression
data of HCV-related HCC tissues to address the following
questions: (1) How do the lipid metabolic genes (LMGs) change
in their expressions during HCC formation and reprogram
the lipid metabolism in cancer? (2) What signatures do the
co-expression network for lipid metabolism-related genes have
and how does the network evolve as the disease advances




The microarray gene-expression data of 75 liver tissue samples
derived from GEO (GSE6764) were analyzed in this study. This
dataset consists of 10 normal tissue samples and 65 disease
samples collected from patients with HCV infection: 13 cirrhotic
tissue samples, 17 dysplastic nodules, and 35 HCC samples.
Methods
Identification of Differentially Expressed Genes
The microarray raw data were normalized by using RMA
(Irizarry et al., 2003). For the genes with multiple probes only
those with the largest mean of expression across the total samples
were retained. The final dataset consists of the expression of
22,880 genes that have official gene symbols. Differential gene
expression between disease sample sets (cirrhosis, dysplasia,
and HCC) and a normal sample set were determined using
limma (Ritchie et al., 2015; Phipson et al., 2016), in which the
Benjamini-Hochberg (BH) method was used for multiple testing.
Differentially expressed genes (DEG) are defined as those meeting
two criteria: adjusted p-value <0.01 and | log2FC| > 1, where FC
denotes a fold change.
Gene Set Enrichment Analysis
Gene set/pathway enrichment analysis was done against GO
terms (Ashburner et al., 2000; The Gene Ontology Consortium,
2017) using ClusterProfiler (Yu et al., 2012) with minor
modifications: (1) the DEGs in each disease sample set were
used as a query gene set, and p-values were computed separately
for the up-regulated and down-regulated genes using the
hypergeometric test; (2) if a GO term or KEGG pathway was
enriched by both up-regulated and down-regulated genes (“BH”
adjusted p-value <0.01), the term with the smaller p-value was
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FIGURE 1 | Venn diagrams for the DEGs in cirrhotic, dysplastic, and HCC samples. (A) Up-regulated genes. (B) Down-regulated genes. (C) Up-regulated lipid
metabolic genes. (D) Down-regulated lipid metabolic genes.
used; (3) for an enriched pathway, if the fraction of the up-
regulated genes (or down-regulated genes) in the DEGs mapped
to the pathway was at least 60%, we considered the pathway
“activated” (or repressed).
Lipid Metabolic Genes
LMGs refer to genes that are involved in the lipid metabolism,
which were obtained from GO1. LMGs in the following GO terms
were analyzed in this study (Supplementary Table S1): fatty acid
biosynthesis (GO: 0006633), β oxidation (GO: 0006635), lipid
biosynthetic process (GO: 0008610), lipid catabolic process (GO:
0016042), lipid metabolic process (GO: 0006629), cholesterol
1http://www.geneontology.org/
metabolic process (GO: 0008203), cholesterol transport (GO:
0030301), and lipid transport (GO: 0006869). The integrated
LMG set had 1,619 unique genes.
Consistently Regulated LMGs and Stage-Specific
LMGs
Consistently up-regulated (or down-regulated) LMGs were
defined as those up-regulated (or down-regulated) in all stages
vs. control samples. Stage-specific LMGs were those satisfying
the following criteria: (1) the genes were up-regulated (or
down-regulated) at a specific disease stage vs. control samples,
but either down-regulated (or up-regulated) or not differentially
expressed at all other stages; and (2) the genes were differentially
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FIGURE 2 | A heat-map for the differentially expressed lipid metabolic genes. Rows and columns represent genes and samples, respectively, and gene names are
given in Supplementary Table S1. Expression values of each gene were centralized at the mean of normal samples and divided by the standard deviation of all
samples.
expressed at a specific disease stage as compared with each of
the other stages.
Inference of Gene Co-Expression Network
A pair of genes were considered as co-expressed if their
expression levels across the specified samples had a strong
correlation, namely Pearson’s correlation: | R| > 0.5 and “BH”
adjusted p-value <0.05.
Stage-Specific Co-expression Networks
We considered a co-expression network as specific to a particular
stage of liver disease, namely normal, cirrhosis, dysplastic or
HCC, if each pair of co-expressed genes in the network (1) was
specific to the disease stage; and (2) its correlation type (positive
vs negative) was different in this stage from those in all the other
stages. The co-expressed genes were visualized using Cytoscape
(Shannon et al., 2003).
Survival Analysis
Survival analysis was performed by using GEPIA (Tang et al.,
2017), which is based on TCGA expression data. The Liver
Hepatocellular Carcinoma (LIHC) samples were divided into two
groups based on the expression levels of a specific gene of interest
(group cutoff: median), and a log-rank test was used to test the
difference in the overall survival between the two groups.
RESULTS AND DISCUSSION
Pathways Enriched in Each Pathological
Stage of HCC
We identified 235, 74, and 827 DEGs in cirrhotic tissues,
dysplastic nodules, and HCCs, respectively, compared with the
controls (Table 1). The percentage of LMGs in the DEGs at
cirrhotic and dysplastic stages were both at ∼10%, but increased
to 22% (180/827) in HCC (Table 1). We noted that more than
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FIGURE 3 | Representative GO terms enriched by the DEGs in cirrhotic (A), dysplastic (B), and HCC samples (C). A term marked as “up” indicates that it is
activated, and “down” represents that it is repressed. The list of enriched GO terms is given in Supplementary Table S2.
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FIGURE 4 | The deviation of LMGs from controls in their expression (| logFC|)
has weak positive correlations (Pearson correlation) with the connectivity of
LMGs.
half of the differentially expressed genes in dysplasia overlapped
with those in the cirrhotic samples (Figures 1A,B). Two
LMGs (AKR1B10 and GOLM1) were consistently up-regulated
(Figure 1C) and two (CYP2C19 and DGAT2) were consistently
down-regulated (Figure 1D). Among the differentially expressed
LMGs, three were cirrhosis-specific up-regulated genes, eight
were HCC-specific up-regulated genes, and 46 were HCC-specific
down-regulated genes (Table 1 and Supplementary Table S1).
The gene expression heat-map (Figure 2) shows that
differentially expressed LMGs roughly fell into four groups:
consistently down-regulated, HCC-specific down-regulated,
HCC-specific up-regulated, and cirrhosis-specific up-regulated
group which was composed of a few genes. The largest one was
the HCC-specific down-regulated group.
We performed pathway-enrichment analyses over each set
of DEGs. The results, as shown in Figure 3, were: (1) in
cirrhotic tissues, multiple immune responses, such as interferon
gamma-mediated signaling, cytokine-mediated signaling, T cell
activation, and response to virus were activated. Extracellular
structure organization, cell adhesion, and cell motility were
also up-regulated; (2) in dysplastic nodules, immune activity
remained up-regulated as in cirrhosis, and apoptotic signaling
was activated; (3) in HCC (Figure 3C), the cell cycle accelerated
as indicated by the increased nuclear division and chromosome
segregation. Chromosome condensation, particularly at the
centromeric region, increased. While no GO terms and pathways
were enriched by down-regulated genes in both cirrhotic
tissues and dysplastic nodules, numerous activities, particularly
the small molecule metabolic process (e.g., carboxylic acid
metabolism) were substantially repressed in HCC. The lipid
metabolic processes were reprogramed in HCC: both the
catabolism and anabolism of lipids and fatty acids were down-
regulated, compared with controls. The reduced oxidation-
reduction process might have been caused by the lack
of O2 inside the cells; and the decreased biosynthesis of
NAD+ indicated the reduced activities of the TCA cycle
FIGURE 5 | Heat-maps for stage-specific co-expression networks of lipid metabolic genes. (A) Cirrhotic-specific co-expression. (B) Dysplastic-specific
co-expression. (C) HCC-specific co-expression. The Pearson’s correlation coefficients are color-coded as depicted in the sidebar. The co-expressed gene-pairs in
the heat-maps are provided in Supplementary Table S3.
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FIGURE 6 | GO terms enriched by the genes co-expressed with LMGs in the stage-specific networks. Enriched GO terms for dysplastic-specific network (A) and
HCC-specific network (B). No GO terms were enriched for cirrhotic samples. The top 20 biological process-associated GO terms with small adjusted p-values are
shown.
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TABLE 2 | The LMGs differentially expressed in disease samples or having high connectivity in disease-specific networks.
DEGs Highly connected LMGsb
Cirrhotic-specific Up: CFTR, ITGB8, SH3YL1 ——
Down: none
Dysplastic-specific Up: none ——
Down: none
HCC-specifica Up: GPC3, PRKAA2 PLSCR4, MFSD2A, ETFDH, ESR1, HAO2, BCO2,
CYP4V2, PTK2, ACAT1, HSD17B6
Down: CYP1A2, CYP39A1, ACSM3, LCAT, MFSD2A, PTGS2, APOF, EGR1,
ESR1, CETP, RDH16, HAO2, MOGAT2, APOA5, BCO2, THRSP, GBA3,
SLCO1B3, CYP2B6, ADH4, CYP2A6, CYP2C8
Consistently regulated or Up: AKR1B10, GOLM1 ST8SIA4, INPP4A, CRYL1
highly connected Down: CYP2C19, DGAT2
aOnly the differentially expressed HCC-specific genes with | log2FC| > 2 and adjusted p-value <0.01 are shown, and the full gene list is given in Supplementary Table S1.
bThe genes are differentially expressed LMGs (| log2FC| > 1 and adjusted p-value <0.01) having the highest 10% connectivity in stage-specific networks.
and fatty acid β-oxidation (Stein and Imai, 2012; Zhu et al.,
2019).
Co-expression Network for Lipid
Metabolic Genes
Pathway enrichment analyses over the DEGs in HCC revealed
evident alterations in lipid metabolism in HCC. To gain
knowledge about other genes that might be strongly associated
with the LMGs at each stage of the disease progression,
we performed co-expression analyses between the LMGs and
other genes. We focused on those non-LMG genes with direct
interactions with lipid metabolism, and hence analyzed only
the first neighbors of LMGs in the network. We first built a
co-expression network for each disease stage.
By analyzing the co-expression networks, we noted that the
extent of the differential expression of the LMGs had weak
positive correlations with the connectivity of LMGs for disease
samples (Figure 4), indicating that the highly differentially
expressed LMGs tended to have more interactions with others.
In addition to marker gene expression (Yan et al., 2020)
and within-sample relative expression orderings (Zhang Z.M.
et al., 2020), the gene co-expression pattern also served as a
diagnostic signature. Particularly, stage-specific co-expression
networks revealed important information for understanding the
disease progression as well as serving as diagnostic or prognostic
markers of the disease (Li et al., 2015; Xu et al., 2016; Chen et al.,
2017; Liu et al., 2018; Yin et al., 2018; Zhang M. et al., 2020).
Moreover, such networks, like dynamical network biomarkers,
can also be used to detect the pre-disease state (Chen et al.,
2012; Liu et al., 2013). We identified stage-specific co-expressions
for LMGs (Supplementary Figure S1). A stage-specific co-
expression refers to that occurring only in a specific stage. Hence
the gene-gene correlations for a specific disease stage differ from
those in the other stages (Figure 5). For the cirrhotic samples,
the stage-specific co-expressions were rare and did not form a
network; but for dysplastic and HCC samples, a large fraction of
the co-expressed genes were connected in a group and formed a
network module (Supplementary Figure S1).
We performed GO term enrichment analyses to detect GO
terms enriched by genes strongly co-expressed with LMGs (|
R| > 0.7, adjusted p-value <0.05) in stage-specific networks.
The results indicated that numerous genes co-expressed with
LMGs play roles in protein localization and the catabolic process
in dysplastic samples, while, in HCC samples, enriched cell
cycle genes were co-expressed with LMGs (Figure 6). This
implied again that cancer was distinct from pre-cancerous lesions
(dysplasia) in regulating the lipid-associated process. No enriched
terms were found for the cirrhotic samples.
In the stage-specific networks, nodes having high connectivity
(e.g., hub genes) might be particularly important. The LMGs with
the highest 10% connectivity present in all three disease stages
(consistently highly connected) and the highly connected LMGs
in the stage-specific networks are listed in Table 2.
By performing survival analysis using GEPIA (Tang et al.,
2017), we found that the expressions of some HCC-specific or
consistently regulated LMGs (shown in bold in Table 2) showed
significant correlations with the survival of patients (Figure 7).
Note that the microarray data of HCC analyzed here were
derived from HCC samples with HCV infection, and hence the
co-expression network constructed by the LMGs may represent
changes of molecular interactions specific to HCV-derived HCC
rather than common changes in HCC of various etiologies. It
remains to be tested if the specific interactions are present in HCC
of other etiologies. Although the mechanisms by which the co-
expressed genes contributed to hepatocellular carcinoma are still
unclear, our results deepen the understanding of HCV-originated
HCC and provide useful information about the stage-specific
signature for HCC.
Reprogramed Lipid Metabolism in HCC
In the above analyses, we used the following criteria to define
a DEG: | logFC| > 1 and adjusted p-value <0.01, which
may miss some differentially expressed genes. To avoid this
issue, we examined the expressions of crucial LMGs particularly
those encoding the enzymes that catalyze the lipid metabolism
using a less stringent criterion: adjusted p-value <0.01. The
analyzed crucial LMGs here were collected from literature
(Baenke et al., 2013; Beloribi-Djefaflia et al., 2016; Cheng et al.,
2018). The results, as given in Figure 8, have revealed that:
(1) the de novo synthesis of fatty acids from citrate acids
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FIGURE 7 | Correlations between survival rates and the expression levels of HCC-specific or consistently regulated LMGs (shown in bold in Table 2).
was enhanced based on the expressions of ACLY, SCD, and
ELOVL in HCC (FASN was marginally up-regulated in HCC:
logFC = 0.58, p = 0.03, adjusted p-value = 0.08), but not evidently
up-regulated in cirrhosis and dysplasia as the key enzymes
for the first and the last steps of fatty acid synthesis, ACLY
and FASN, did not show differential expressions in these two
disease stages; (2) down-regulation of multiple apolipoprotein
genes in HCC, which can transport lipids between the liver,
peripheral cells, and blood, as well as the repressed lipoprotein
receptors suggest that HCC may be independent on lipids in
blood circulation; the down-regulated lipid importers, FABP1
and S1PR5, also support this independence prediction; the
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FIGURE 8 | Expression levels of key LMGs in HCV-derived HCC. (A) A heat-map for these genes in HCC vs. controls (GSE6764), where the displayed numbers are
logFC values. Only the DEGs with adjusted p-value <0.01 are shown, and the full list of genes analyzed here is given in Supplementary Table S1. ACSL4 is
categorized into a lipid synthesis group according to its role found in (Doll et al., 2017); (B) A schematic depiction of the reprogramed lipid metabolism in HCC.
Different colors are used to mark differential expressions: pink, blue, and green represent up-regulation, down-regulation, and no significant changes, respectively.
The results of differential expression analysis and GO enrichment analysis suggest increased de novo synthesis of fatty acids, reduced lipid exchange between HCC
tumor and its environment, and down-regulated lipid catabolic process and fatty acid oxidation in HCC.
substantial down-regulation of LCAT and CETP suggests that
there is almost no reverse cholesterol transport into HCC; the
slightly up-regulation of APOL2 and APOL3, apolipoproteins
that may assist the movement of lipids in the cytoplasm or
allow the binding of lipids to organelles, possibly suggests
the requirement of lipids at subcellular locations in HCC;
(3) no lipid degradation in HCC was detected, as indicated
by the down-regulated lipases, LIPC, LIPG, and MGLL; (4)
ACSL1 and ACSL6, enzymes that catalyze the degradation
of long chain fatty acids, were down-regulated in HCC, but
interestingly, another enzyme, ACSL4, of the same family
was considerably up-regulated; (5) the enzyme for promoting
triglyceride synthesis and downstream lipid droplet formation,
DGAT2, was significantly down-regulated in cirrhosis, dysplasia,
and HCC, which might be a natural consequence of the protein-
energy malnutrition from the cirrhotic stage; (6) the reduced
expression of PTGS2 (Cyclooxygenase 2) suggested the reduced
production of prostaglandin, a pro-inflammatory signal, in HCC;
(7) three enzymes, AGPAT2, PPAP2B, and PPAPDC1B, involved
in phospholipid synthesis from fatty acids were down-regulated,
while two other enzymes in this pathway, AGPAT1 and PPAP2A,
were up-regulated; (8) the first step of cholesterol synthesis,
ACAT2, was down-regulated in HCC, but the second step,
HMGCS1, was up-regulated.
We also analyzed an additional microarray data (GSE14323)
consisting of 19 normal, 58 HCV-cirrhotic, and 47 HCV-
HCC samples to see if the results mentioned above could be
rediscovered. Overall, the results derived from GSE14323 agreed
well with that of GSE6764 (Supplementary Figure S2), and
revealed two additional findings: (1) FABP4 and FABP5 were
up-regulated in HCC; (2) EVOL6 was down-regulated in HCC.
Note that although the members of the ACSL family convert
free long-chain fatty acids into fatty acyl-CoA esters, thereby
playing a key role in fatty acid degradation, ACSL4 was
reported to play a special role in phospholipid synthesis and
ferroptosis (Doll et al., 2017). We therefore speculate that the
increased expression of ACSL4 in HCC promotes the synthesis
of phospholipids. Fatty acid binding proteins FABPs are thought
to play roles in fatty acid uptake, transport, and metabolism
(McKillop et al., 2019). FABP1 is primarily expressed in liver,
while FABP4 is in adipocytes. Not only adipocyte-derived FABP4
affects cancer development, FABP4 expressed in hepatocytes was
also reported to promote HCC progression (Thompson et al.,
2018; McKillop et al., 2019). Consistently, we observed high
expression of FABP4 in HCC. The exact mechanisms by which
FABP4, FABP5, and EVOL6 function in HCC need further
studies to uncover.
Our data strongly suggest a reduced lipid exchange between
an HCC tumor and its environment. Hence we postulate that the
lipids required for building the membrane of the proliferating
cancer cell is intracellularly synthesized. Although the analysis
on key enzymes is unable to give a clear picture about fatty acid
degradation in HCC, our GO enrichment results clearly support
that fatty acid oxidation is down-regulated in HCC.
It is worth noting that there might be strong inter- and intra-
tumoral heterogeneity, which could be ascribed to (epi)genetic
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lesions, microenvironmental constraints, stromal interactions,
and treatment effects (Park et al., 2018). Even for a specific
cancer type, lipid metabolism may differ between cancer subtypes
(Monaco, 2017; Koundouros and Poulogiannis, 2020). For
example, receptor-positive and triple-negative breast cancers
have notable differences in terms of lipid procurement, storage,
and oxidation (Monaco, 2017). Therefore, we need to put
special emphasis on the heterogeneity of lipid metabolism
across and within tumors in cancer studies and lipid-
targeted cancer therapy.
Putting these all together, we can conclude that: (1) HCC
cells tend to de novo synthesize fatty acids and its phospholipid
derivatives; (2) the lipid catabolic process and fatty acid oxidation
are greatly repressed in HCC; (3) the lipid metabolism in
HCC is largely independent of lipids in blood circulation; (4)
the co-expression network for LMGs shows a dynamic change
during the process of HCC development, and stage-specific
co-expression networks for LMGs are identified; (5) several
HCC-specific differentially expressed LMGs and some LMGs in
HCC-specific network are associated with the cancer survival.
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